Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 11Gastrointestinal 8Head & Neck 5Other solid neoplasm 4Sarcoma 3CNS 3Other neoplasm 1Genitourinary 1Endocrine 1

Conditions

Urinary Bladder Neoplasms 1Photosensitivity Disorders 1Non-Muscle Invasive Bladder Neoplasms 1

Interventions

Docetaxel 409pembrolizumab 331Prednisone 290enzalutamide 285Gemcitabine 274Radiotherapy 270Magnetic Resonance Spectroscopy 269Nivolumab 253Abiraterone Acetate 218Cisplatin 212Leuprolide 195Radiosurgery 192Sunitinib 188Carboplatin 161Androgen Antagonists 156bicalutamide 152Specimen Handling 149Goserelin 149Ipilimumab 131Paclitaxel 126acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide 122apalutamide 118Cyclophosphamide 117Bevacizumab 116Sorafenib 114Everolimus 111abiraterone 108cabozantinib 105atezolizumab 105Biopsy 101

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Dihematoporphyrin Ether × Genitourinary × Clear all
NCT00322699 2012-10-26

Sequential Whole Bladder Photodynamic Therapy (WBPDT) in the Management of Superficial Bladder Cancer

North Florida/South Georgia Veterans Health System

Phase 1/2 Completed
22 enrolled
Genitourinary

Non-Muscle Invasive Bladder Neoplasms, Urinary Bladder Neoplasms, Photosensitivity Disorders

Data powered by HemOnc (CC BY 4.0) Colophon âš¡